Systemic phosphorus pool

The systemic phosphorus pool refers to the total distribution of phosphorus, primarily as inorganic phosphate, across the extracellular fluid, intracellular spaces, and the hydroxyapatite matrix of bone [StatPearls, 2023]. It is a vital physiological compartment essential for skeletal mineralization, cellular energy transfer via ATP, and the structural integrity of cell membranes and nucleic acids [NIH ODS, 2023]. Homeostasis of this pool is maintained by a complex endocrine network involving the kidneys, intestines, and bone, regulated by parathyroid hormone (PTH), vitamin D, and fibroblast growth factor 23 (FGF23) [Nature Reviews Nephrology, 2015]. Pathological shifts in the pool, such as hyperphosphatemia in chronic kidney disease, are linked to increased cardiovascular mortality and bone disease, while hypophosphatemia leads to rickets and muscle weakness [PubMed, 2019]. Pharmacological management does not target the pool as a single molecule but rather modulates it through phosphate binders that limit intestinal intake or biologics that alter renal handling [FDA, 2018]. Consequently, the systemic phosphorus pool is a critical clinical parameter for monitoring metabolic health and the efficacy of renal and endocrine therapies.

Other names

Phosphate poolBody phosphorus storesSerum phosphateInorganic phosphate poolExtracellular phosphorus

Drugs modulate the systemic phosphorus pool through several mechanisms: intestinal phosphate binders (e.g., Sevelamer) sequester dietary phosphate to prevent absorption; FGF23 inhibitors (e.g., Burosumab) increase renal phosphate reabsorption; and NHE3 inhibitors (e.g., Tenapanor) reduce paracellular phosphate absorption in the gut [StatPearls, 2023; Nature Reviews Nephrology, 2015].